Recombinant IGF-1 therapy in insulin-dependent diabetes mellitus;Therapeutique par l'IGF-1 recombinant au cours du diabete de Type 1

Diabetes and Metabolism

Volumn 22, Issue 4, 1996, Pages 257-260

  Savage, M O ^a   Dunger, D B ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

adolescent insulin dependent diabetes mellitus; glycaemic control; growth hormone; recombinant insulin like growth factor I

Indexed keywords

INSULIN; RECOMBINANT SOMATOMEDIN C; GROWTH HORMONE; RECOMBINANT PROTEIN; SOMATOMEDIN C;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SCREENING; HORMONAL THERAPY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; REVIEW; ADOLESCENT; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; METABOLISM; REFERENCE VALUE;

ADOLESCENT; CONTROLLED CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; RECOMBINANT PROTEINS; REFERENCE VALUES;

EID: 0030191512     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor 1 in healthy adults. N Engl J Med, 1987, 317, 137-40.
2. Boulware SD, Tamborland WV, Matthews LS, Sherwin RS. Diverse effects of insulin-like growth factor 1 on glucose, lipid and amino acid metabolism. Am J Physiol, 1992, 262, E130-3.
3. Clayton KL, Holly JMP, Carlsson LMS et al. Loss of the normal relationship between growth hormone, growth hormone binding protein and insulin-like growth factor in adolescents with insulin-dependent diabetes mellitus. Clin Endocrinol, 1994, 41, 517-24.
4. Batch JA, Baxter RC, Werther G. Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin-dependent diabetes. J Clin Endocrinol Metab, 1991, 73, 964-8.
5. Taylor AM, Dunger DB, Grant DB, Preece MA. Somatomedin-C IGF-1 measured by radioimmunoassay and somatomedin bioactvity in adolescents with insulin-dependent diabetes mellitus compared with puberty-matched control. Diabetes Res, 1989, 9, 177-81.
6. Taylor AM, Dunger DB, Preece MA et al. The growth hormone independent insulin-like growth factor-1 binding protein BP-28 is associated with serum insulin-like growth factor-1 inhibitory bioactivity in adolescent insulin-dependent diabetes. Clin Endocrinol, 1990, 32, 229-39.
7. Edge JA, Dunger DB, Matthews DR, Gilbert JP, Smith CP. Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab. 1990, 71, 1356-1362.
8. Batch JA, Werther GA. Changes in growth hormone concentrations during puberty in adolescents with insulin-dependent diabetes. Clin Endocrinol, 1992, 36, 411-416.
9. Smith CP, Dunger DB, Williams AJK et al. Relationship between insulin, insulin-like growth factor-1 and dehydroepiandrosterone sulphate concentrations during childhood, puberty and adult life. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 932-937.
10. Cotterill AM, Camacho-Hübner C, Holly JMP, Savage MO. The effect of recombinant human insulin-like growth factor-1 treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron Syndrome). Clin Endocrinol, 1993, 69, 229-231.
11. Cheetham TD, Jones J, Taylor AM, Holly J, Matthews DR, Dunger DB. The effects of recombinant insulin-like growth factor 1 administration on growth hormone levels and insulin requirements in adolescents with Type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1993, 36, 678-681.
12. Cheetham TD, Clayton KL, Taylor AM, Holly JPM, Matthew DR, Dunger DB. The effects of recombinant insulin-like growth factor 1 on growth hormone secretion in adolescents with insulin-dependent diabetes mellitus. Clin Endocrinol. 1994, 40, 515-522.
13. Cheetham TD, Holly JMP, Clayton K, Cwytan-Hughes S, Dunger DB. The effects of repeated daily recombinant human insulin-like growth factor 1 administration in adolescents with type 1 diabetes. Diabetic Medicine, 1995, 12, 885-892.